Cytek Biosciences, Inc.

CTKB

US23285D1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
5.97 ^USD	-0.83%		-2.13%	-34.54%

05-13	Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating	MT
05-08	Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	MT

Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022

May 11, 2022 at 09:05 pm

Cytek Biosciences, Inc. provided revenue guidance for the full year 2022. The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.

Latest news about Cytek Biosciences, Inc.

Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating	05-13	MT
Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	05-08	MT
Transcript : Cytek Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024	05-08	CI
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	03-20	MT
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance	03-19	MT
Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics	03-19	CI
Cytek Biosciences, Inc. Announces CFO Changes	03-19	CI
Cytek Biosciences Unveils New Manufacturing Facility in Wuxi, China	03-08	MT
Cytek Biosciences, Inc. Opens A New 50,000-Square-Foot Facility in Wuxi, China	03-07	CI
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	03-06	MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.	03-01	CI
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024	03-01	CI
Cytek Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Transcript : Cytek Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Cytek Biosciences Agrees to Flow Cytometry Collaboration With Centre for Genomic Regulation, Pompeu Fabra University	01-18	MT
Cytek Biosciences, Inc. Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries	01-17	CI
Cytek Seeks Merger and Acquisitions	01-11	CI
Transcript : Cytek Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	01-11
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023	01-08	CI
Cytek Biosciences Introduces the Cytek Orion? Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry	12-21	CI
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9	12-14	MT
Cytek Biosciences Insider Sold Shares Worth $120,600, According to a Recent SEC Filing	11-21	MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating	11-09	MT

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Sector

Advanced Medical Equipment & Technology

Calendar

04/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cytek Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.97 USD

Average target price

9.8 USD

Spread / Average Target

+64.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYTEK BIOSCIENCES, INC.	-34.54%	790M
THERMO FISHER SCIENTIFIC	+11.31%	225B
DANAHER CORPORATION	+15.50%	197B
INTUITIVE SURGICAL, INC.	+18.83%	143B
BOSTON SCIENTIFIC CORPORATION	+30.38%	111B
SIEMENS HEALTHINEERS AG	+2.62%	64.72B
EDWARDS LIFESCIENCES CORPORATION	+18.31%	54.44B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.96%	51.06B
AGILENT TECHNOLOGIES, INC.	+9.95%	45.03B
GE HEALTHCARE TECHNOLOGIES INC.	+4.27%	37.4B

Other Advanced Medical Equipment & Technology